Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation
Dawwas GK, Brensinger CM, Vajravelu RK, Wu Q, Kelly CR, Laine L, Wu GD, Lewis JD. Long-term Outcomes Following Multiply Recurrent Clostridioides difficile Infection and Fecal Microbiota Transplantation. Clinical Gastroenterology And Hepatology 2020, 20: 806-816.e6. PMID: 33307184, PMCID: PMC8184854, DOI: 10.1016/j.cgh.2020.12.004.Peer-Reviewed Original ResearchConceptsFecal microbiota transplantationIrritable bowel syndromeImmune-mediated diseasesBowel syndromeMyocardial infarctionMicrobiota transplantationRecurrent Clostridioides difficile infectionRecurrent Clostridioides difficileRetrospective cohort studyImmune-mediated conditionsInflammatory bowel diseaseInflammatory bowel syndromeCommercial claims databaseLong-term outcomesClostridioides difficile infectionCohort studyBowel diseaseMicrobiota disturbanceRheumatoid arthritisClaims databaseDifficile infectionHigh riskHigh incidenceGut microbiotaSignificant associationPhysicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey.
Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ, Yang YX, Laine L, Weissman A, Saini SD. Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey. The American Journal Of Gastroenterology 2020, 115: 689-696. PMID: 32091419, PMCID: PMC7196016, DOI: 10.14309/ajg.0000000000000558.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsPPI adverse effectsAdverse effectsHigh riskLong-term PPI useGastroesophageal reflux diseaseMultiple adverse effectsPPI useReflux diseasePPI discontinuationInhibitor riskMost internistsPump inhibitorsPhysicians' perceptionsInternists' perceptionsSignificant associationGeneral medicineDiscontinuationLogistic regressionClinical usePatientsFuture interventionsIndividual riskPreventionUGIB